Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Ms. Krebs joins Sensei from SNIPR Biome, a clinical-stage biotechnology company where, as Chief Business Officer, she was responsible for defining the company’s growth and partnering activities, including value creation through collaborations with large pharmaceutical and biotech partners. Prior to this, she held business and corporate development roles of increasing responsibility in a number of companies, including Valo Health, bluebird bio, HotSpot Therapeutics and Swedish Orphan Biovitrum (Sobi) AB. Ms. Krebs also spent 10 years at Biogen, where she initially supported commercial activities before moving into business development and focused on generating strategic partnerships for the company’s neurology and immunology pipelines. Ms. Krebs holds an MS in biotechnology from Johns Hopkins University and an MBA from the University of Rochester.

“We’re delighted to welcome Stephanie to our leadership team at such an exciting moment for Sensei, as we advance the ongoing Phase 1/2 clinical trial of our lead candidate SNS-101 and prepare to move an additional candidate toward IND-enabling studies,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. “She has a track record of driving strategic alliances that move novel medicines closer to patients while providing fuel for continued pipeline expansion and program development. Her business development expertise and deep understanding of the drug development landscape are critical to executing on our near-term strategic initiatives while planning thoughtfully for the future.”

“Sensei is facing head-on the challenges that have limited innovation in immuno-oncology and has assembled a skilled and highly motivated team,” said Ms. Krebs. “I look forward to joining the team at this exciting stage and leveraging my experience to contribute to the company’s continued progress and growth.”

About Sensei Biotherapeutics:

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39.  For more information, please visit , and follow the company on Twitter @SenseiBio and . 

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of Sensei’s product candidates, the timing of Sensei’s Phase 1/2 clinical trial of SNS-101, including reporting of data therefrom, and the timing of selection of product candidates and IND-enabling studies. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on or about August 3, 2023 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Michael Biega

Senior Director, Investor Relations

Sensei Biotherapeutics

Media Contact:

Chris Railey

Ten Bridge Communications